270 related articles for article (PubMed ID: 25544869)
1. Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out.
Sun H; Zhu MS; Wu WR; Shi XD; Xu LB
World J Hepatol; 2014 Dec; 6(12):830-5. PubMed ID: 25544869
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis in Hepatocellular Carcinoma; Pathophysiology, Targeted Therapy, and Role of Imaging.
Moawad AW; Szklaruk J; Lall C; Blair KJ; Kaseb AO; Kamath A; Rohren SA; Elsayes KM
J Hepatocell Carcinoma; 2020; 7():77-89. PubMed ID: 32426302
[TBL] [Abstract][Full Text] [Related]
4. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
Gao DY; Lin TsT; Sung YC; Liu YC; Chiang WH; Chang CC; Liu JY; Chen Y
Biomaterials; 2015 Oct; 67():194-203. PubMed ID: 26218745
[TBL] [Abstract][Full Text] [Related]
5. A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma.
Zhong L; Fu XY; Zou C; Yang LL; Zhou S; Yang J; Tang Y; Cheng C; Li LL; Xiang R; Chen LJ; Chen YZ; Wei YQ; Yang SY
Int J Cancer; 2014 Dec; 135(12):2972-83. PubMed ID: 24789676
[TBL] [Abstract][Full Text] [Related]
6. A dual-targeting reconstituted high density lipoprotein leveraging the synergy of sorafenib and antimiRNA21 for enhanced hepatocellular carcinoma therapy.
Li M; Su Y; Zhang F; Chen K; Xu X; Xu L; Zhou J; Wang W
Acta Biomater; 2018 Jul; 75():413-426. PubMed ID: 29859368
[TBL] [Abstract][Full Text] [Related]
7. Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone.
Kim HY; Park JW
Dig Dis; 2011; 29(3):303-9. PubMed ID: 21829021
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
[TBL] [Abstract][Full Text] [Related]
9. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
10. Locoregional and systemic therapy for hepatocellular carcinoma.
Gbolahan OB; Schacht MA; Beckley EW; LaRoche TP; O'Neil BH; Pyko M
J Gastrointest Oncol; 2017 Apr; 8(2):215-228. PubMed ID: 28480062
[TBL] [Abstract][Full Text] [Related]
11. Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma.
Tazi el M; Essadi I; M'rabti H; Touyar A; Errihani PH
N Am J Med Sci; 2011 Apr; 3(4):167-75. PubMed ID: 22540086
[TBL] [Abstract][Full Text] [Related]
12. Is the era of sorafenib over? A review of the literature.
Fan G; Wei X; Xu X
Ther Adv Med Oncol; 2020; 12():1758835920927602. PubMed ID: 32518599
[TBL] [Abstract][Full Text] [Related]
13. Multiple Roles of Autophagy in the Sorafenib Resistance of Hepatocellular Carcinoma.
Sun T; Liu H; Ming L
Cell Physiol Biochem; 2017; 44(2):716-727. PubMed ID: 29169150
[TBL] [Abstract][Full Text] [Related]
14. Evolving role of Sorafenib in the management of hepatocellular carcinoma.
Ziogas IA; Tsoulfas G
World J Clin Oncol; 2017 Jun; 8(3):203-213. PubMed ID: 28638790
[TBL] [Abstract][Full Text] [Related]
15. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.
Zhu AX
Expert Opin Investig Drugs; 2010 May; 19(5):663-72. PubMed ID: 20367287
[TBL] [Abstract][Full Text] [Related]
16. Identification of Novel Anti-Liver Cancer Small Molecules with Better Therapeutic Index than Sorafenib via Zebrafish Drug Screening Platform.
Lin HS; Huang YL; Wang YS; Hsiao E; Hsu TA; Shiao HY; Jiaang WT; Sampurna BP; Lin KH; Wu MS; Lai GM; Yuh CH
Cancers (Basel); 2019 May; 11(6):. PubMed ID: 31141996
[TBL] [Abstract][Full Text] [Related]
17. Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma.
Zeng Z; Lu Q; Liu Y; Zhao J; Zhang Q; Hu L; Shi Z; Tu Y; Xiao Z; Xu Q; Huang D
Front Oncol; 2021; 11():641522. PubMed ID: 34307125
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma.
Zhai B; Sun XY
World J Hepatol; 2013 Jul; 5(7):345-52. PubMed ID: 23898367
[TBL] [Abstract][Full Text] [Related]
19. Epithelial-to-Mesenchymal Transition: A Mediator of Sorafenib Resistance in Advanced Hepatocellular Carcinoma.
Mir N; Jayachandran A; Dhungel B; Shrestha R; Steel JC
Curr Cancer Drug Targets; 2017; 17(8):698-706. PubMed ID: 28460616
[TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
